Euretina Logo, Links to homepage.
Euretina Logo, Links to homepage.
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login
  • September 10, 2021
  • 2021 Abstracts

Efficacy of intravitreal aflibercept administered using a treat-and-extend regimen in patients with macular edema secondary to central retinal vein occlusion: Post hoc analysis of the CENTERA study

Author: Jean-Francois Korobelnik (France)

Co-authors: Michael Larsen, Nicole Eter, Clare Bailey, Sebastian Wolf, Kay Rittenhouse, Helmut Allmeier

Purpose

The aim of the CENTERA study was to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) administered using a proactive, individualized treat-and-extend (T&E) dosing regimen in patients with macular edema secondary to central retinal vein occlusion (CRVO). The primary results, including safety, of the CENTERA study have been previously published. This post hoc analysis of the CENTERA study assessed baseline (BL) characteristics, treatment intervals, as well as functional (best-corrected visual acuity [BCVA]) and anatomic (central retinal thickness [CRT]) outcomes of patients who achieved treatment success based on study criteria similar to LEAVO (BCVA of ≥83 letters achieved at any point during treatment).

Setting/Venue

CENTERA (NCT02800642) was a 76-week, multicenter, open-label, single-arm, Phase 4 study performed at 42 sites in Canada, Europe, and Australia. Treatment-naïve patients aged ≥18 years with center-involved macular edema secondary to CRVO, and BCVA of 73–24 Early Treatment Diabetic Retinopathy Study (ETDRS) letters in the study eye were enrolled.

Methods

Patients with macular edema secondary to CRVO received 2 mg IVT-AFL injections at BL and every 4 weeks until disease stability criteria were met, or until Week 20, whichever occurred first (initiation phase). The treatment interval was adjusted in 2-week increments based on functional and anatomic outcomes, as assessed by the investigator (T&E phase). Monitoring occurred at each injection and mandatory visit (Weeks 24, 52, and 76). Co-primary endpoints were the proportion of patients who gained ≥15 letters from BL to Week 76 and the proportion of patients with a mean treatment interval of ≥8 weeks from the last initiation phase visit to Week 76. Safety was assessed throughout the study. A post hoc sensitivity analysis of the second co-primary endpoint was conducted based on study criteria similar to LEAVO for treatment success. In this sensitivity analysis, patients who achieved ≥83 letters at any point were considered treatment successes and, therefore, to have met the second co-primary endpoint of achieving a mean treatment interval of ≥8 weeks. The proportion of patients who maintained robust vision gains (achieved ≥83 letters and did not lose >5 letters thereafter) was also assessed.

Results

The full analysis set (FAS) comprised 160 patients (n=74 [≥83 letter group; mean±SD BL BCVA 61.2±12.3] and n=86 [<83 letter group; BL BCVA 44.0±16.2]). Overall, 65.6% (n=105; 95%CI, 57.7–72.9, p<0.0001 [test against 40% threshold]) of patients in the FAS gained ≥15 letters from BL to Week 76. During the T&E phase, 45.0% (n=72; 95%CI, 37.1–53.1, p=0.8822 [threshold of 50%]) of patients in the FAS achieved a mean treatment interval of ≥8 weeks. In the sensitivity analysis of the second co-primary endpoint, where patients who achieved ≥83 letters at any point were considered treatment successes and therefore to have met this endpoint, 66.3% (n=106; 95%CI, 58.4–73.5, p<0.0001 [50% threshold]) of patients achieved a mean treatment interval ≥8 weeks or treatment success during the T&E phase. Of the patients who achieved ≥83 letters at any point, 54.1% (n=40) maintained vision. Mean change in BCVA from BL to Week 76 was +23.9±13.6 (≥83 letter group) letters and +17.3±23.1 (<83 letter group) letters. At BL, mean CRT was 695.6±226.4 (≥83 letter group) µm and 816.6±249.9 (<83 letter group) µm. Mean change in CRT from BL to Week 76 was −419.8±235.0 (≥83 letter group) µm and −563.4±249.3 (<83 letter group) µm.

Conlusions

In the CENTERA study, clinically meaningful and significant improvements in functional and anatomic outcomes were achieved with IVT-AFL administered using a proactive, individualized T&E regimen in patients with macular edema secondary to CRVO. An appreciable proportion of patients in CENTERA achieved high BCVA (≥83 letters) following IVT-AFL T&E treatment. This sensitivity analysis indicated that, if similar criteria to LEAVO for treatment success had been used, most patients could have achieved a mean treatment interval of ≥8 weeks or treatment success during the T&E phase. Of the patients who achieved ≥83 letters at any point during the study, over half not only achieved, but also remained at ≥83 letters. In addition, patients who achieved ≥83 letters at any point during the study had higher BCVA and lower CRT at BL, compared with those who did not achieve ≥83 letters. In both groups, patients demonstrated BCVA gains and improved CRT, demonstrating that IVT-AFL administered using a proactive, individualized T&E regimen optimizes visual acuity gains and normalizes CRT irrespective of BL status.

Financial Disclosure

Jean-François Korobelnik: Consultant for Allergan, Bayer, Janssen, Kanghong, Novartis, Novonordisk, Roche, Thea, Zeiss Michael Larsen: Study investigator and consultant for (and the Rigshospitalet has received compensation for clinical trials from) AbbVie, Acucela, Alcon, Allergan, Bayer, GlaxoSmithKline, Novartis, and Novo Nordisk Nicole Eter: Consultant for Alimera, Allergan, Bayer, Novartis, Roche Clare Bailey: Attendance at advisory boards/lecture fees for Alimera Sciences, Bayer, Novartis, and Roche Sebastian Wolf: Consultant for Allergan, Bayer, Heidelberg Engineering, Novartis, Optos Inc, Roche, Zeiss; Grant support from Heidelberg Engineering Kay Rittenhouse: Employee of Bayer Consumer Care AG, Basel, Switzerland Helmut Allmeier: Employee of Bayer Consumer Care AG, Basel, Switzerland Tobias Machewitz: Employee of Bayer AG, Berlin, Germany Varun Chaudhary: Grants from Allergan Inc, Bayer Healthcare, and Novartis Pharma AG; Scientific advisor for Alcon Laboratories, Bayer Healthcare, and Novartis Pharma AG; Advisory board member for Roche Funding: The CENTERA study was funded by Bayer AG, Germany. Medical writing support was provided by ApotheCom, and funded by Bayer Consumer Care AG, Pharmaceuticals, Switzerland.

Comments

Important add below co-authors: 7. Tobias Machewitz: Bayer AG, Berlin, Germany 8. Varun Chaudhary: Hamilton Regional Eye Institute, St. Joseph’s Healthcare Hamilton, McMaster University, Hamilton, ON, Canada
PrevPrevious
NextNext
Euretina Logo, Links to homepage.

European Society of Retina Specialists c/o Congrex Switzerland
Reinacherstrasse 131
4053 Basel
Switzerland

T +41 61 686 77 91
F +41 61 686 77 88

General Enquires: [email protected]

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Euretina 2026 Vienna

Ophthalmologica

Forum

Opportunities

Memberships

About

Code of Conduct

Privacy Policy

Contact Us

Newsletter Sign up

By clicking 'Subscribe', you agree to the terms of our Privacy Policy. 
 
 

Follow us

© EURETINA 2026 All rights reserved

  • Events
    • Euretina 2027 Copenhagen
      • Session Submission Terms
    • EuretinaAI: AI in Retina
    • Special Focus Meeting 2027 – Inherited Retinal Diseases
      • Registration
      • Poster Submission
      • Programme
    • Euretina 2026 Vienna
      • On-Demand
      • Congress Daily
      • Welcome
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
        • Wet Labs
        • WSPOS X EURETINA Paediatric Retina Day
        • World Retina @ Euretina
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Abstract Submission
      • Session Submission
      • Euretina Innovation Spotlight (EIS) 2026
      • General Information
        • FAQs
        • Euretina Run
        • Delegate Party
        • Sustainability Plan
        • Meeting Policy
        • Travel Details
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2026 – AI in Retina
      • Registration
      • Post-Event Hub
      • Hotels
      • Programme
      • Keynote
      • Poster Submission
    • Euretina 2025 Paris
      • 2025 Paris On Demand
      • Welcome
      • Congress Daily & Photo Gallery
      • Registration
      • Hotels
      • Programme
        • Keynote Lectures
      • Abstracts
      • Satellite Symposia
      • Abstract Submission
      • Late Breaking Submissions
      • EuroVeRsion Case Contest
      • Exhibitors & Sponsors
      • Euretina Innovation Spotlight (EIS)
      • General Information
        • Sustainability Plan
        • Travel Details
        • Delegate Party
        • Women in Retina Networking Breakfast
        • Press Details
        • Social Media Toolkit
    • Special Focus Meeting 2025 – Ocular Endotamponades
      • About
      • Programme
      • Poster & Video Presentations
    • Future Meetings
    • Upcoming Digital Events
  • Free Resources
    • Webinars
    • Podcasts
    • Case Club Cases
    • Euretina Guidelines
    • Euretina Brief
    • IME ePlatform
  • Membership
  • About
    • Euretina Board
    • Committees
    • Subspecialty Sections
    • Code of Conduct
    • Bye-laws
    • Our Sustainability Commitment
    • 25th Anniversary
      • Euretina Congresses 2001-2025
      • A History of Euretina
  • Opportunities
    • Observership Grant Programme – OPEN
    • RMCR Award Programme – OPEN
    • Mentorship Programme
      • Mentorship Alumni
    • Ramin Tadayoni Award
    • Jacqueline Cigrang AMD Research Grant
    • EBO-Euretina Exam
    • YOURS
      • Ophthalmologica Lecturer Proposal
    • Women in Retina
      • Overview
      • Women in Retina Committee
      • Women in Retina Survey 2026
      • Women in Retina Networking Breakfast 2026
      • Women in Retina Networking Breakfast 2025
      • Interview with Anat Loewenstein
      • Women in Retina Interviews 2025
      • Women in Retina Interviews 2023
      • Euretina White Paper on Gender Diversity
      • Euretina Survey on Gender Diversity
    • BEAVRS VR Database
    • CME Credits
  • Member Login